Clinical Trials on Bi-polar II Disorder in Norway

Total 45 results

Oslo University Hospital
University of Oslo

Recruiting

Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia (FH-FEMINA)

Familial Hypercholesterolemia

Norway
Nordlandssykehuset HF
Pronova BioPharma

Completed

Effect of Omega-3 Fatty Acid on Endothelial Function

Familial Hypercholesterolemia

Norway
University of Bergen
Karolinska Institutet; University of Copenhagen; Technical University of Munich; University of Glasgow

Recruiting

Dietary Strategies for Remission of Type 2 Diabetes (CARBCOUNT)

Hypertension | Diabetes Mellitus, Type 2 | Insulin Resistance | Glucose Intolerance | Overweight and Obesity | Dyslipidemia Associated With Type II Diabetes Mellitus

Norway
University of Oslo
Oslo University Hospital; Mills DA

Completed

Postprandial Response After Intake of Meals With Different Fatty Acid Composition

Healthy | Familial Hypercholesterolemia

Norway
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia

Pediatric Heterozygous Hypercholesterolemia

Greece, Norway, Canada
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

Canada, France, Netherlands, Norway
Medical Research Laboratories International

Terminated

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Familial Hypercholesterolemia

Netherlands, United States, Norway
Medical Research Laboratories International

Terminated

Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy

Familial Hypercholesterolemia

Israel, Netherlands, United States, Canada, Norway
LIB Therapeutics LLC
Medpace, Inc.

Completed

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (LIBerate-FH)

Heterozygous Familial Hypercholesterolemia

United States, Israel, Norway, South Africa, Turkey
Haukeland University Hospital
Karolinska University Hospital; Oslo University Hospital; University Hospital... and other collaborators

Recruiting

MicroRNA as Markers in Testicular Cancer

Seminoma | Testicular Germ Cell Cancer | Non-Seminoma Testicular Cancer | Stage I Testicular Cancer | Stage II Testicular Cancer | Stage III Testicular Cancer | Stage IV Testicular Cancer | Relapse Testicular Cancer

Norway, Sweden
AstraZeneca

Completed

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Familial Hypercholesterolaemia

United States, Netherlands, Norway, Canada, Belgium
AstraZeneca

Completed

PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin

Familial Hypercholesterolemia

United States, Spain, Netherlands, Norway, Canada
LIB Therapeutics LLC

Completed

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Homozygous Familial Hypercholesterolemia

United States, Israel, Norway, South Africa, Turkey, India
Sanofi
Regeneron Pharmaceuticals

Completed

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS)

Hypercholesterolaemia

Norway, Russian Federation, Sweden, South Africa, Czechia, United States, Canada, France, Netherlands, Spain
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) (ODYSSEY FH II)

Heterozygous Familial Hypercholesterolemia

United Kingdom, Netherlands, Czech Republic, Norway
LIB Therapeutics LLC
Medpace, Inc.

Enrolling by invitation

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (LIBerate-OLE)

Familial Hypercholesterolemia | Elevated Cholesterol | Cardiovascular Disease With Mention of Arteriosclerosis

United States, Israel, Norway, South Africa, Turkey, India
Shire

Completed

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Hunter Syndrome | Mucopolysaccharidosis II (MPS II)

United States, France, United Kingdom, Germany, Sweden, Spain, Brazil, Canada, Italy, Romania
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Atorvastatin Three Year Pediatric Study

Familial Hypercholesterolemia

United States, Spain, Turkey, Canada, Belgium, Germany, Greece, Hungary, Italy, Norway, Poland, Puerto Rico, Russian Federation, Slovakia, Switzerland
Amgen

Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Hyperlipidemia

Canada, France, Netherlands, United Kingdom, New Zealand, South Africa, Spain, United States, Australia, Germany, Sweden, Hong Kong, Switzerland, Norway
Pfizer

Completed

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Hyperlipidemia | Hypercholesterolemia, Familial

Australia, Canada, United States, France, South Africa, Sweden, Norway, Denmark, Iceland
NewAmsterdam Pharma

Active, not recruiting

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. (BROOKLYN)

Dyslipidemias | Hypercholesterolemia | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Familial Hypercholesterolemia | Metabolic Disease | High Cholesterol | Genetic Disease, Inborn | Lipid Metabolism Disorder

United States, Canada, Czechia, Georgia, Netherlands, Norway, Poland, South Africa, Spain, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Hypercholesterolaemia

Czechia, France, Denmark, Netherlands, Austria, Mexico, Spain, United States, Argentina, Brazil, Bulgaria, Canada, Finland, Hungary, Italy, Lebanon, Norway, Poland, Russian Federation, Slovenia, South Africa, Sweden, Taiwan, Turkey
Amgen

Completed

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) (HAUSER-OLE)

Familial Hypercholesterolemia

Canada, Italy, Norway, Belgium, United States, Turkey, Australia, Austria, South Africa, Poland, Switzerland, Spain, Portugal, Slovenia, Brazil, Russian Federation, Hungary, United Kingdom, Colombia, Czechia, Netherlands, Greece, Ma...
Forest Laboratories
Phenomix

Terminated

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Diabetes Mellitus, Type II

United States, Belarus, India, Romania, Germany, Lithuania
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Germany, Japan, Korea, Republic of, Mexico, Norway, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (V-PEDS-OLE)

Heterozygous or Homozygous Familial Hypercholesterolemia

Netherlands, Israel, Hungary, Italy, Germany, Spain, United States, France, Norway, Russian Federation, South Africa, Turkey, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, Poland, Taiwan, Malaysia
Novartis Pharmaceuticals

Active, not recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (ORION-16)

Familial Hypercholesterolemia - Heterozygous

United States, Germany, South Africa, Greece, Italy, Czechia, Taiwan, Slovakia, Turkey, France, Russian Federation, Canada, Spain, Jordan, Switzerland, Hungary, Poland, Netherlands, Norway, United Kingdom, Lebanon, Argentina, Brazil, ... and more
Amgen

Completed

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (HAUSER-RCT)

Heterozygous Familial Hypercholesterolemia

United States, Canada, Italy, Norway, Belgium, Turkey, Australia, New Zealand, Austria, Czechia, South Africa, Poland, Spain, Switzerland, Netherlands, Taiwan, Finland, Brazil, Portugal, Slovenia, Russian Federation, Hungary, United... and more
Pfizer

Completed

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (SPIRE-FH)

Heterozygous Familial Hypercholesterolemia

Canada, Netherlands, United Kingdom, United States, Spain, Poland, Finland, Norway, South Africa, Italy, Bulgaria
National Cancer Institute (NCI)

Terminated

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, South Africa
Kastle Therapeutics, LLC

Completed

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH)

Hypercholesterolemia | Heterozygous Familial

United States, Italy, Poland, Ukraine, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Argentina, Belgium, Israel, Malaysia, South Africa, Turkey, Netherlands, Korea, Republic of, Canada, New Zealand, Russian Federation, Brazil, Austral... and more
Daiichi Sankyo, Inc.

Terminated

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

Atherosclerosis | Heterozygous Familial Hypercholesterolemia

United States, United Kingdom, Spain, South Africa, Israel, Canada, Netherlands, Norway, Sweden
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States, Saudi Arabia, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pain | Urinary Complications | Breast Adenocarcinoma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | Metastatic Malignant Neoplasm to the Bone | Musculoskeletal Complication

United States, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Obesity | Fatigue | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Neurotoxicity Syndrome

United States, Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Mixed Mesodermal (Mullerian) Tumor | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage... and other conditions

United States, Korea, Republic of

Clinical Trials on Bi-polar II Disorder in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations